Dr. Alexander Bausch Ph.D., MTE (IMD)
Dr. Alexander Bausch serves as Chief Executive Officer and member of the Strekin Board of Directors. Dr. Bausch has extensive commercial, development and executive leadership expertise from a 20 year career in the pharmaceutical industry. Prior to founding Strekin, he worked as an independent consultant strategically supporting venture capital funds and small biotech companies.
Claudia Berger is Director, Head of Clinical Operations at Strekin. She gained her expertise from more than 15 years in the pharmaceutical industry and is leading all clinical trial projects at Strekin in collaboration with external vendors. Prior this Ms. Berger headed the clinical trial operations unit at Delenex Therapeutics AG in Zürich.
Dr. Viktor Boerlin M.D.
Dr. Viktor Boerlin is the Chief Medical Officer at Strekin. Dr. Boerlin worked for over 30 years for Sandoz/Novartis and Hoffmann-La Roche in different positions and therapeutic areas overseeing drug development encompassing Phase 1 to Phase 4 clinical trials. At Sandoz, he led the Department of Neuroendocrinology in clinical R&D where he was responsible for the clinical sections of seven registration filings.
Dr. Urs Breitenstein
Dr. Urs Breitenstein serves as Chief Financial Officer at Strekin. Dr. Breitenstein is a partner at Hoffmann & Co. AG, one of the leading Corporate Finance and CFO services companies for the life sciences industry in Switzerland.
Dr. Corinne Peter, M.D.
Dr. Peter is currently Head of Project Management at Strekin. Most recently, Dr. Peter was Medical Director at Pierre Fabre, Switzerland, where she was responsible for dermatological drugs and for quality, regulatory, vigilance und medical information (QRVI) for cosmetic products.
Dr. Matthew Wright Ph.D.
Dr. Matthew Wright is Chief Operating Officer, Head of Research at Strekin. Dr. Wright is a seasoned scientific leader with 15 years of experience in drug discovery research. Dr. Wright most recently served as Research Leader and Scientific Expert at Hoffmann La Roche.